Kazia registers 232,956 ADSs in new prospectus

Rhea-AI Filing Summary

Kazia Therapeutics Limited (KZIA) filed a prospectus supplement covering 232,956 American Depositary Shares (ADSs), which represent 116,478,000 ordinary shares, and updating its Form F-1 prospectus with a September 18, 2026 Form 6-K. The company has appointed JPMorgan Chase Bank, N.A. as sole depositary for its American Depositary Receipt program, replacing The Bank of New York Mellon. Under a Second Amended and Restated Deposit Agreement, each ADS now represents 500 ordinary shares, and the ADSs will continue to trade on Nasdaq under the symbol KZIA. Existing ADS holders are told no action is required and the transition is expected to be seamless.

Filing Explained

This filing updates an existing prospectus with the ADR-program report; it does not disclose a new ADS sale, offering price, proceeds, or completed issuance, so its disclosed effect is administrative rather than a financing transaction.

Key Figures

ADSs covered by prospectus: 232,956 ADSs Ordinary shares represented: 116,478,000 ordinary shares ADS-to-ordinary-share ratio: 500 ordinary shares per ADS +2 more

5 metrics

ADSs covered by prospectus 232,956 ADSs Amount referenced on the prospectus supplement cover

Ordinary shares represented 116,478,000 ordinary shares Ordinary shares represented by the 232,956 ADSs

ADS-to-ordinary-share ratio 500 ordinary shares per ADS Ratio under the Second Amended and Restated Deposit Agreement

Last reported ADS price $10.86 per ADS Last reported sale price on Nasdaq on September 17, 2026

Form 6-K date September 18, 2026 Date of the Form 6-K incorporated into the prospectus supplement

Key Terms

American Depositary Shares, American Depositary Receipt, Deposit Agreement, foreign private issuer, +1 more

5 terms

American Depositary Shares financial

"JPMorgan will issue American Depositary Shares (“ADSs”), each representing"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

American Depositary Receipt financial

"as the sole depositary for the Company’s American Depositary Receipt (“ADR”) program"

An American depositary receipt (ADR) is a certificate that represents shares of a foreign company traded on U.S. stock exchanges. It allows investors to buy and sell parts of a foreign company's stock easily, much like purchasing shares of a company based in their own country. ADRs make international investing more convenient and accessible for U.S. investors.

Deposit Agreement financial

"entered into a Second Amended and Restated Deposit Agreement (the “Deposit Agreement”)"

A deposit agreement is a written contract between a customer and a financial institution that outlines the terms for opening and maintaining a deposit account, such as a savings or checking account. It explains important details like how funds can be accessed, any fees involved, and the institution’s responsibilities. For investors, understanding this agreement is important because it clarifies their rights and the rules governing their deposited funds.

foreign private issuer regulatory

"REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

Form F-6 regulatory

"JPMorgan has filed a Registration Statement on Form F-6 with the"

Form F-6 is an SEC registration form used when a U.S. depositary bank creates American Depositary Receipts (ADRs), which are certificates that let U.S. investors buy and sell shares of a foreign company as if they were domestic stocks. Think of an ADR as a local-language label placed on a foreign product: it makes the foreign share easier to trade and settle in U.S. markets, increasing accessibility, liquidity and investor choice while bringing certain U.S. disclosure and regulatory oversight.

Offering Details

shelf

Offering

Offering Type shelf

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Kazia Therapeutics (KZIA) register in this prospectus supplement?

The supplement relates to 232,956 American Depositary Shares, which represent 116,478,000 ordinary shares, and updates the existing Form F-1 prospectus with information from a Form 6-K dated September 18, 2026.

What change did KZIA make to its ADR program in September 2026?

On September 18, 2026, Kazia Therapeutics appointed JPMorgan Chase Bank, N.A. as the sole depositary for its ADR program, replacing The Bank of New York Mellon, under a Second Amended and Restated Deposit Agreement.

What is the ADS-to-ordinary-share ratio for KZIA after this change?

Under the new Deposit Agreement, each Kazia Therapeutics American Depositary Share (ADS) represents 500 ordinary shares of the company.

Will the KZIA ADSs continue trading on Nasdaq and under what symbol?

Yes. The company states that its ADSs will continue to trade on The Nasdaq Capital Market under the symbol “KZIA.”

Do existing KZIA ADS holders need to take any action due to the new depositary?

No. Kazia Therapeutics states that ADS holders do not need to take any action, the transition is expected to be seamless, and existing ADS holders will continue to hold their positions without interruption.

What was the last reported Nasdaq sale price for KZIA ADSs before this supplement?

The last reported sale price of Kazia Therapeutics ADSs was $10.86 per ADS on The Nasdaq Capital Market on September 17, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/18/2026 - 04:07 PM Accepted by SEC EDGAR 09/18/2026 - 04:03 PM Learn about SEC filing dates

Filed Pursuant to Rule 424(b)(3)

Registration No. 333-290598

PROSPECTUS SUPPLEMENT

(to Prospectus dated December 23, 2025)

232,956 American Depositary Shares representing

116,478,000

Ordinary Shares

 

Kazia Therapeutics Limited

This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 23, 2025 (the “Prospectus”), which forms a part of our Registration Statement on Form F-1 (Registration No. 333-290598), as amended, with the information contained in our current report on Form 6-K, furnished to the Securities and Exchange Commission on September 18, 2026 (the “September 18, 2026 Form 6-K”). Accordingly, we have attached the September 18, 2026 Form 6-K to this prospectus supplement.

This prospectus supplement updates and supplements the information in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This prospectus supplement should be read in conjunction with the Prospectus and if there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement.

The ADSs are listed on The Nasdaq Capital Market (“Nasdaq”) under the symbol “KZIA.” On September 17, 2026, the last reported sale price of the ADSs on Nasdaq was $10.86 per ADS.

Investing in our securities involves a high degree of risk. See “Risk Factors” beginning on page 9 of the Prospectus and the “Risk Factors” in “Item 3. Key Information-D. Risk Factors” of our most recent Annual Report on Form 20-F, which is incorporated by reference in the Prospectus, as well as in any other recently filed reports and, if any, in any applicable prospectus supplement.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of the Prospectus or this prospectus supplement. Any representation to the contrary is a criminal offense.

The date of this prospectus supplement is September 18, 2026

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2026

Commission File Number: 000-29962

Kazia Therapeutics Limited.

(Exact Name of Registrant as Specified in Its Charter)

Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

On September 18, 2026, Kazia Therapeutics Limited (the “Company”) appointed JPMorgan Chase Bank, N.A. (“JPMorgan”) as the sole depositary for the Company’s American Depositary Receipt (“ADR”) program, replacing The Bank of New York Mellon (“BNY Mellon”). In connection with the appointment, the Company and JPMorgan entered into a Second Amended and Restated Deposit Agreement (the “Deposit Agreement”), pursuant to which JPMorgan will issue American Depositary Shares (“ADSs”), each representing five hundred (500) of the Company’s ordinary shares. The ADSs will continue to trade on The Nasdaq Capital Market under the symbol “KZIA.” JPMorgan has filed a Registration Statement on Form F-6 with the Securities and Exchange Commission in connection with the new ADR program. ADS holders do not need to take any action at this time. The transition is expected to be seamless, and existing ADS holders will continue to hold their positions without interruption.

Incorporation by Reference

The Company hereby incorporates by reference the information contained herein into the Company’s registration statements on Form F-3 (File Nos. 333-276091, 333-281937 and 333-294392).

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Kazia Therapeutics Limited.
Date: September 18, 2026	By:	/s/ John Friend
	Name:	John Friend
	Title:	Chief Executive Officer

2